<DOC>
	<DOC>NCT00206024</DOC>
	<brief_summary>This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.</brief_summary>
	<brief_title>Acid-Associated Heartburn Symptoms and Dose of Esomeprazole</brief_title>
	<detailed_description />
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Males and nonlactating females, aged 18 to 75 years, inclusive, with the ability to understand English and provide written informed consent A history of heartburn for at least 6 months A history of prior positive relief of heartburn symptoms from antacids or acid suppressive therapy A positive esophageal acid perfusion test At least 3 days of 'moderate' severity heartburn over the previous 7 days No use of any acid suppression therapy (PPI, H2RA, etc.) within 14 days of randomization A history of gastric or esophageal surgery H. pylori positive A history of endoscopy verified erosive esophagitis within the 16 weeks prior to randomization Currently taking higher than the standard approved proton pump inhibitor doses Historical evidence of a number of other GI, cardiovascular, pulmonary, liver, kidney, pancreatic, cerebral vascular diseases, organ transplant, or a condition requiring surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>